NCT07223580 A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi
| NCT ID | NCT07223580 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Mayo Clinic |
| Condition | Ureteroscopy |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-01-23 |
| Primary Completion | 2027-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 90 participants in total. It began in 2026-01-23 with a primary completion date of 2027-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to evaluate if corticosteroid (prednisone) after ureteroscopy and placement of the stent will help alleviate postoperative pain control in addition to other normal postoperative pain medications
Eligibility Criteria
Inclusion Criteria: * Patients who are diagnosed with kidney or ureteral stones confirmed on imaging (CT of the abdomen or pelvis) and who elect for definitive treatment via ureteroscopy with placement of ureteral stent. * Age 18 years or older * Patients of either gender * Patients of all ethnic backgrounds * Cable of giving informed consent * Capable and willing to fulfill the requirements of the study. Exclusion Criteria: * History of chronic pain * Chronic use of opioids or other pain medication (\>12 weeks) * Known allergies to corticosteroids. * Known or suspected pregnancy * Inability to give informed consent or unable to meet requirements of the study for any reason. * Bilateral ureteroscopy * Current Corticosteroid Use * Diabetic patients who are insulin dependent
Contact & Investigator
Rev V. Vilasan Shylaja
📞 480-574-1466
Karen L. Stern, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT07223580 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ureteroscopy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07223580 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07223580 currently recruiting?
Yes, NCT07223580 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.
Where is the NCT07223580 trial being conducted?
This trial is being conducted at Scottsdale, United States.
Who is sponsoring the NCT07223580 clinical trial?
NCT07223580 is sponsored by Mayo Clinic. The principal investigator is Karen L. Stern, MD at Mayo Clinic. The trial plans to enroll 90 participants.